MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.
2 reports, 1 independent
Updated Aug 17
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
MarketBeat
American personal finance blog
Related events
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
- MarketBeat is providing consensus price targets and analyst recommendations for consumer staples companies, including JBS S.A. and Inspire Veterinary Partners.
- Information Services Group and MarketBeat are being compared financially, with MarketBeat providing analyst recommendations for the company.
- MarketBeat uses for analyst ratings and competes in the medical device market, involving Teleflex and Vasamed.